Steven Fruchtman
President at TRAWS PHARMA, INC.
Net worth: 117 042 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Christina Merrill | F | - |
Bone Marrow & Cancer Foundation, Inc.
 Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | 32 years |
| Mark Guerin | M | 55 | 11 years | |
| Robert Fishman | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| James Marino | M | 74 | 9 years | |
| Trafford Clarke | M | 66 | 2 years | |
| Jack Stover | M | 69 | 8 years | |
| Mary Shoemaker | F | 63 | 4 years | |
| Charlotte Moss | F | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Andrew Robin | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Aimee Eberle | F | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Sergio Giralt | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Victor Moyo | M | - | 1 years | |
| Matthew Parris | M | - | 6 years | |
| Michael A. Grabow | M | - | 11 years | |
| Suleika Jaouad | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Evan Handler | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Harry Pearce | M | 81 |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Vasilianna Fakiris | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Lisa M. Eastman | F | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Meg Braff | F | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Seun Adebiyi | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Calvert S. Moore | F | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Jonathan Alter | M | - |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Michael E. Schick | M | 57 |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 15 years |
| Stephen D. Nimer | M | 70 |
Bone Marrow & Cancer Foundation, Inc.
Bone Marrow & Cancer Foundation, Inc. Miscellaneous Commercial ServicesCommercial Services The Bone Marrow Foundation is a non profit organization which offers financial assistance and free support services to bone marrow or stem cell transplant patients and their families. The company was founded by Christina Merrill in 1992 and is headquartered in New York, NY. | - |
| Meena Arora | F | - | 1 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joseph W. Turgeon | M | 66 | 9 years | |
| Thomas Riga | M | 48 | 10 years | |
| Richard Shea | M | 72 | 6 years | |
| Ramesh Kumar | M | 68 | 21 years | |
| Ajay Bansal | M | 62 | 3 years | |
| Kurt Gustafson | M | 56 | 9 years | |
| Michael Hoffman | M | 73 | 18 years | |
| Ivor Royston | M | 79 | 4 years | |
| Peter Atadja | M | 64 | 2 years | |
| George W. Sledge | M | 73 | 3 years | |
| Dolatrai Vyas | M | 80 | 9 years | |
| Robert Fralin | M | - | - | |
| Fabrice Egros | M | 62 | 9 years | |
| Krishan K. Arora | M | 83 | 3 years | |
| Nishan de Silva | M | 51 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| Gilles Gagnon | M | 70 | - | |
| E. Premkumar Reddy | M | 80 | 22 years | |
| Raymond Cohen | M | 65 | 7 years | |
| Anton G. Gueth | M | 67 | 1 years | |
| Jerome Groopman | M | 72 | 11 years | |
| David Stout | M | 69 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 3 years |
| Viren Mehta | M | 74 | 20 years | |
| Anne VanLent | F | 76 | 3 years | |
| Lee F. Allen | M | 72 | 3 years | |
| Al DeJesus | M | - | - | |
| Luke Seikkula | M | 60 | 3 years | |
| Richard C. Woodman | M | 69 | 3 years | |
| Dilip J. Mehta | M | 91 | 2 years | |
| Jennifer Carver | F | 70 | 2 years | |
| Abraham Noah Oler | M | 48 | 4 years | |
| Dennis Kim | M | 55 | 1 years | |
| Adar Makovski Silverstein | M | - | 2 years | |
| Pablo Cagnoni | M | 60 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 years |
| Thomas J. McKearn | M | 75 | 4 years | |
| Kenneth Joseph Keller | M | 61 | 2 years | |
| James E. Shields | M | 72 | 2 years | |
| Brian Holzer | M | - | - | |
| Mark Gelder | M | 67 | 2 years | |
| Charles Q. Morris | M | 59 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 2 years |
| Michael D. Casey | M | 78 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 8 years |
| Kerry Clem | M | 54 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 1 years |
| George Uy | M | 67 | 4 years | |
| Pamela Klein | M | 63 | - | |
| Manoj Maniar | M | 60 | 15 years | |
| Stewart John Hen | M | 57 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 5 years |
| George Tidmarsh | M | 64 | 1 years | |
| James Caruso | M | 65 |
Allos Therapeutics, Inc.
Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | 4 years |
| Michael Saunders | M | - | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 74 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Steven Fruchtman
- Personal Network
